Clinical Research of Huanglian Jiedu Decoction for Intervention of Dyslipidemia
10.13359/j.cnki.gzxbtcm.2015.06.005
- VernacularTitle:黄连解毒汤干预血脂异常的临床研究
- Author:
Xueren OUYANG
;
Zaoyuan KUANG
;
Wei WU
- Publication Type:Journal Article
- Keywords:
Huanglian Jiedu Decoction/therapeutic use;
Dyslipidemia /TCD therapy;
Metabolism;
Hepatic function
- From:
Journal of Guangzhou University of Traditional Chinese Medicine
2015;32(6):993-995,999
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the effect of Huanglian Jiedu Decoction ( HJD) for the treatment of dyslipidemia, thus to provide evidence for the prevention and treatment of dyslipidemia with traditional Chinese medicine. Methods A total of 80 dyslipidemia patients were randomized into HJD group ( 50 cases) and simvastatin group ( 30 cases) . After treatment for 4 weeks, blood lipid levels, metabolic parameters and alanine aminotransferase (ALT) levels were detected. Results (1) After treatment, HJD group and simvastatin group both had lower total cholesterol (TC), triglyceride (TG), low density lipoprotein cholesterol levels (P<0.01 compared with those before treatment), and HJD group had higher high density lipoprotein cholesterol than that before treatment ( P<0.05), but the differences of TC, TG, low and high density lipoprotein cholesterol were insignificant between the two groups ( P>0.05). ( 2) After treatment, uric acid was reduced in HJD group ( P<0.05) , but fasting blood glucose only showed a decreasing trend and the other metabolic parameters stayed unchanged ( P>0.05). The inter-group comparison showed that HJD had lower blood glucose level than simvastatin group, and the difference had statisticall significance ( P<0.05). ( 3) During the treatment, the patients showed good compliance, and had no obvious hepatic or renal damage. Conclusion HJD could reduce TC, TG and low density lipoprotein cholesterol, and increase high density lipoprotein cholesterol of dyslipidemia patients, the effect being similar to simvastatin. HJD could also significantly reduce uric acid of dyslipidemia patients, showing good safety.
